Searched for
BIOCON IPO
Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under reviewBiocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company i...13 Nov, 2025, 07.16 AM IST- Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran ShawBiocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity,...15 May, 2025, 12.19 AM IST
- Biocon appoints Peter Bains as Group CEO"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...18 Sep, 2023, 09.50 PM IST
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...01 Mar, 2022, 10.05 AM IST
- Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw"And obviously, we expect the IPO to be at a very, very attractive level. So if you look at it, it's going to hugely create value for share...28 Feb, 2022, 06.11 PM IST
- First pharma IPO in 5 years: Syngene’s debut offer subscribed 32 timesThe Rs 550-crore initial public offer of Syngene, a research arm of Biocon, was subscribed 32 times on the final day of the offer31 Jul, 2015, 12.30 PM IST
- Syngene's valuations are fair, investors need to invest in its growth story: Kiran Mazumdar-ShawIn an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about the Syngene IPO and the growth prospects involved.27 Jul, 2015, 12.56 PM IST
- Management commentary, capex outlook hold the key for Biocon: Mayuresh JoshiIf you look at how the business model has evolved for Biocon, Syngene is the one which is driving the overall profitability for the company...24 Jul, 2015, 02.33 PM IST
- Biocon sets Syngene IPO price band at Rs 240-250Biocon plans to raise Rs 550 crore by diluting 11% stake in Syngene through the Initial Public Offer. The proceeds will mostly go into fund...17 Jul, 2015, 08.27 PM IST
- Syngene IPO opens July 27; price band at Rs 240-250; Biocon shares end in redBiocon's subsidiary Syngene has set the price band for its forthcoming IPO at Rs 240-250 per share that will open on July 27.16 Jul, 2015, 05.22 PM IST
- Plan to list Syngene in August, use IPO proceeds for R&D: Kiran Mazumdar-ShawSyngene International, present in the contract services business, had filed its draft red herring prospectus (DRHP) with Sebi .24 Jun, 2015, 01.07 PM IST
- Syngene gets FIPB nod to raise foreign investment to 44%Syngene, a subsidiary of Biocon, said it has received the Foreign Investment Promotion Board approval to raise foreign investment to 44 per...22 Jun, 2015, 05.56 PM IST
- Bullish on Dr Reddy's, Lupin among pharma names; Biocon still not a 'buy': Pankaj PandeyPandey believes that tiel I drug makers could get faster ANDA approvals. He expects the US market to continue to drive growth for domestic ...16 Jun, 2015, 02.56 PM IST
- Analysis: Can Syngene IPO Change Biocon's Fortunes?Contributing one-fourth of the consolidated revenues, Syngene has been Biocon's best-performing segment in the last couple of years.28 Apr, 2015, 12.56 PM IST
- Stocks of QIP candidates more promising than forthcoming IPOsThe QIP activity has taken off very well, says Diwan. Ashoka Buildcon has come to the market at the right time, he adds.16 Apr, 2015, 08.53 AM IST
- Syngene dragged too far as value proposition; avoid Biocon: Prakash DiwanWhile Syngene has a healthy pipeline of biosimilars, the monetisation of some of the molecules could take up to six years, says Diwan.01 Apr, 2015, 02.55 PM IST
- Biocon to sell up to 25% in Syngene via IPOBiocon will launch an IPO for its fully-owned contract research subsidiary Syngene this financial year.23 Apr, 2008, 03.52 AM IST
Load More
